Promoting Wound Healing with Gene Therapies and Birch Bark Extract

Epidermolysis bullosa (EB) requires an interdisciplinary management approach tailored to the diagnosed EB subtype. Recently, new therapeutic approaches have been approved to improve symptomatic treatment. While a gel formulation containing a highly concentrated dry extract of birch bark received Swissmedic approval last year, Beremagen-Geperpavec is currently not approved in Switzerland—unlike in the EU and the U.S. Another innovative treatment option with FDA approval is Prademagen-Zamikeracel.